Advertisement
Advertisement
TOPIC

New medical drugs

New medical drugs
Latest news and updates on medical drug research and breakthroughs.
Axiom Biosciences joins a swelling roster of healthcare firms seeking IPO approval in Hong Kong. Photo: Shutterstock
Banking & finance

Healthcare IPO wave: US biotech firm picks Hong Kong over Nasdaq for listing

Axiom Biosciences founder says Hong Kong investors show greater maturity than Nasdaq in handling biotech companies.

China’s private sector

‘Systemic leap’: China’s drug innovation push yields bumper crop

videocam
United States

Lab monkey prices soar as China’s biotech boom fuels windfall for breeders

China’s private sector

China’s biotech boom: RAS-targeted drugs challenge US dominance

The rapid development of China’s RAS-targeted cancer drugs could reshape global oncology and unlock the country’s undervalued biotech firms.

Chinese biotech and innovative drug firms are rapidly closing the gap with its US rivals as it continues to develop RAS-targeted cancer therapies. Photo: Shutterstock
China’s private sector

Which company could become the Chinese Pfizer? Here are analysts’ top picks

A boom in outlicensing agreements leads to a debate over which Chinese firms may be first to break into overseas markets with own brands.

China manufacturing

China extols potential of AI in guideline on marine biopharmaceuticals

Ministry of Natural Resources urges research institutions and drug makers to use the technology to speed up the development of new drugs.

Advertisement
Advertisement
Advertisement
Biomedicine: Companies

China’s Innovent Biologics signs US$10.5b Pfizer deal for 12 cancer drug trials

The agreement covers eight early-stage trials from Innovent and four discovery programmes from global giant Pfizer.

videocam
A researcher uses a microscope in a cancer research laboratory. Photo: Shutterstock
Science

Chinese team uses supercomputer to cut drug screening time from years to seconds

AI platform that can screen vast library of chemical compounds opens up new frontiers in fight against cancer and infectious diseases.

videocam
Science

Does China’s Jiuzhang 4.0 computer herald the age of quantum supremacy?

New programmable photonic quantum computing prototype completed a complex calculation in microseconds, developers say.

United States

Trump says US Food and Drug Commissioner Marty Makary is out

The FDA chief’s departure follows weeks of intensifying pressure from powerful Republicans, anti-abortion groups and others.

FDA Commissioner Marty Makary attends an event at the White House in April. Photo: AP
China’s private sector

How China’s ‘landmark’ drug pricing guidelines could be a boon for biotech

State Council calls for ‘value-based pricing’ for innovative drugs, a move researchers said would benefit private healthcare players.

Chinese biotech firms reached 157 agreements to out-licence early-stage drugs last year. Photo: Shutterstock
India

Opinion | Asia’s flood of cheap Ozempic generics opens gates to weight-loss abuse

Cheaper semaglutides as patent ends is good news for diabetics. But lax regulation also means a risk of abuse by those desperate to lose weight.

videocam
Biomedicine: Companies

China biotech deals hit record as innovative drugs draw global interest

Deals reach US$60 billion in first quarter after analysts say Chinese biotech firms have shown substantial technological advancements.

China’s private sector

Rights to antibody drug from China’s Keymed change hands in US acquisition

Sichuan-based Keymed expects to receive up to US$320 million as a result of deal involving its autoimmune disease treatment licensed in 2024.

Gilead Sciences is one of many drug firms facing a revenue gap owing to expiring patents. Photo: Reuters
China’s private sector

Wave of Chinese biotech deals builds with US$1.2 billion Harbour BioMed pact

Deal involving an antibody asset ‘goes beyond a traditional licensing transaction’, founder and CEO says.

Harbour BioMed’s antibody programme focuses on tumour-killing effects. Photo: Handout
China’s crackdowns

China charges former AstraZeneca executive – a sign of the times?

Foreign drug makers face pressure in the Chinese market, from tighter regulatory oversight to growing local competition.

Hong Kong healthcare and hospitals

Repurposed kidney drug may offer hope to infertile women, Hong Kong study finds

Researchers say finerenone may provide affordable treatment with few side effects for women affected by premature ovarian insufficiency.

Advertisement
Advertisement
Advertisement
Hong Kong healthcare and hospitals

Exclusive | No prescription, no problem: Hong Kong’s grey zone for weight-loss injections

Slimming injections cannot be sold or purchased in Hong Kong without doctor’s prescription, but some retailers are operating grey market.

Weight-loss injections, which have been approved by Hong Kong authorities for use, have become increasingly popular around the world. Photo: Karma Lo
Wellness

Weight rebound after stopping Ozempic, Wegovy? Not necessarily, new data says

New research suggests that many people who stop using GLP-1 drugs like Ozempic maintain their weight loss, countering previous studies.

China’s private sector

China’s drug and medical device sector fuels growth with record licensing deals

China’s pharmaceutical industry surges on ageing demand and global expansion, with revenue forecast to top US$2.1 trillion by 2030.

Made in China 2025

Novartis, SciNeuro deal offers hope for 55 million suffering from Alzheimer’s

SciNeuro’s anti-amyloid programme is one of the firm’s key strategic research and development priorities to target the brain disease.

videocam
Swiss drugmaker Novartis has gained global rights over SciNeuro’s novel amyloid beta targeted antibody programme. Photo: Reuters
Made in China 2025

Meow or never: China’s pudgy pets spark race for weight-loss drugs

Fosun and Huadong biotech labs eye feline obesity drugs as owners weigh cuteness against health risks.

The total pet population in China reached 430 million in 2024, with nearly one-third of urban cats classified as obese, according to the China Pet Industry Association. Photo: Shutterstock
Artificial intelligence

MindRank in Phase 3 trial with first AI-assisted new drug

The company was aiming for approval in the second half of 2028, paving the way for a market launch in 2029.

Science

China’s biopharma sector ‘in prime position to challenge US leadership’

American commission issues stark warning, as analytics firm Clarivate reports that Chinese innovative drug development has entered new phase.

videocam
33
Hong Kong healthcare and hospitals

Genomic sequencing puts Hong Kong at forefront of cancer care innovation

Scientist Aya El Helali says research speeds up cancer treatment discovery and helps the city bridge mainland China with global drug development.

Aya El Helali is a clinical assistant professor at the University of Hong Kong’s department of clinical oncology. Photo: Jonathan Wong
Wellness

As weight-loss drugs reduce appetites, US restaurants cut portion sizes

Some New York restaurants are offering smaller portions at lower prices to appeal to those on hunger-reducing GLP-1 weight-loss medications.

A chef at Le Petit Village in New York prepares half-sized portions of their brunch menu items, designed to appeal to people taking GLP-1 weight-loss medications, on December 10, 2025. Photo: AFP
Medicine

No need for needles? US approves Wegovy pill for weight loss

Novo Nordisk’s daily medication offers an oral alternative to blockbuster injections, with a launch expected in early January.

United States

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement